title: [Recent aspects of therapy with androgenic and anabolic steroids].
abstract: From the pharmacology of the therapeutically available androgen preparations and the clinical experience results that a highly dosed androgen long-term therapy is effectively possible only by testosterone esters which are to be injected intramuscularly (e.g. testosterone oenanthate). It is indicated in all forms of endocrine hypogonadism, certain aplastic anaemias and if necessary in extreme male high growth. In partial androgen deficiency (pubertas tarda, Klinefelter's syndrome, climacterium virile and others) orally applicable androgens such as testosterone-undecanoate (Andriol) and mesterolone (Vistimon) can be used. The latter is to be preferred when a hyperoestrogenism is present, e.g. in liver cirrhosis. When 17-alpha-alkylated oral androgens are used, their often not sufficiently confirmed anabolic effect and their potential liver toxicity should more be taken into consideration.
mesh_terms: D000293:Adolescent; D045930:Anabolic Agents / Q000627:therapeutic use*; D000728:Androgens / Q000009:adverse effects / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male
chemical_list: D045930:Anabolic Agents; D000728:Androgens
vernacular_title: Neuere Aspekte in der Therapie mit Androgenen und anabolen Steroiden.